Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer.
Loss of expression of HLA class I antigens has been demonstrated in a wide variety of tumors and is considered to be one of the mechanisms whereby tumors escape T-cell surveillance. Genomic DNA of MHC class I/II molecules in seven lung cancer cell lines was investigated and compared with that in peripheral blood mononuclear cells. In three cell lines, OU-LC-A1, OU-LC-A2, and OU-LC-AS1, a loss of HLA haplotype was observed. Aberrations of HLA class I/II in tumor cell lines should be considered when MHC-restricted phenomena in vitro models are assessed and clinical use of tumor vaccination in vivo is considered.
Hiraki
A
A
Second Department of Medicine, Okayama University Medical School, Japan.
Kaneshige
T
T
Kiura
K
K
Ueoka
H
H
Yamane
H
H
Tanaka
M
M
Harada
M
M
D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000276:immunology*; D004247:DNA / Q000235:genetics; D006680:HLA Antigens / Q000235:genetics*; D006239:Haplotypes; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D007157:Immunologic Surveillance; D008175:Lung Neoplasms / Q000235:genetics / Q000276:immunology*; D008297:Male; D010641:Phenotype; D016133:Polymerase Chain Reaction; D012703:Serotyping; D014407:Tumor Cells, Cultured
D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D004247:DNA